• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    7/22/26 5:30:42 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $COEP alert in real time by email
    false 0001759186 0001759186 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): July 17, 2026

     

     

     

    Z SQUARED INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39669   98-1465952
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    550 South Andrews Ave., Suite #700

    Fort Lauderdale, Florida

      33301
    (Address of principal executive offices)   (Zip Code)

     

    305-697-0792

    (Registrant’s telephone number, including area code)

     

    ________________________________________

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   ZSQR   The Nasdaq Global Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.02 Termination of a Material Definitive Agreement.

     

    On July 17, 2026, Z Squared Inc. (the “Company”) delivered written notice terminating (i) the At Market Offering Agreement, dated July 6, 2026 (the “ATM Sales Agreement”), with Roth Capital Partners, LLC, as sales agent, pursuant to which the Company was permitted to offer and sell shares of its common stock, par value $0.0001 per share, having an aggregate offering price of up to $300,000,000 from time to time under the Company's automatic shelf registration statement on Form S-3 (the “ATM Program”), and (ii) the Committed Equity Forward Purchase Agreement, dated May 29, 2026 (the “Forward Purchase Agreement”), with Translucent Matter Inc., pursuant to which the Company had the right, but not the obligation, to require the purchaser to purchase up to $50,000,000 of shares of the Company's common stock from time to time.

     

    The termination of the ATM Sales Agreement will be effective July 21, 2026, and the termination of the Forward Purchase Agreement will be effective August 17, 2026, in each case in accordance with the notice provisions of the applicable agreement. The Company will not sell, draw down or issue any shares of common stock under either program during the applicable notice period. No termination fee or penalty is payable by the Company in connection with either termination. No shares of common stock were sold under the ATM Program, no draws were made and no shares were issued under the Forward Purchase Agreement, and neither agreement obligated the Company to issue or sell any shares of common stock absent further action by the Company. 

     

    Item 7.01 Regulation FD Disclosure

     

    On July 17, 2026, the Company issued a press release announcing the termination of the ATM Sales Agreement and the Forward Purchase Agreement described in Item 1.02 above. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    The information set forth under this Item 7.01, including Exhibit 99.1, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    99.1   Press Release dated July 17, 2026, titled “Z Squared Inc. Terminates At-The-Market Sales Agreement and Committed Equity Forward Purchase Agreement.”
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: July 22, 2026

     

      Z SQUARED INC.
       
      By: /s/ David Halabu
      Name: David Halabu
      Title: Chief Executive Officer

     

    2

     

     

    Get the next $COEP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COEP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $COEP
    SEC Filings

    View All

    Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Z Squared Inc. (0001759186) (Filer)

    7/22/26 5:30:42 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Z Squared Inc. (0001759186) (Filer)

    7/10/26 4:00:56 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Z Squared Inc. (0001759186) (Filer)

    7/7/26 5:08:43 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COEP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market

    ~ Shares to Commence Trading on the Nasdaq Global Market Under Ticker Symbol "ZSQR" Monday April 27, 2026 ~FORT LAUDERDALE, Fla, April 24, 2026 /PRNewswire/ -- Z Squared, Inc. (NASDAQ:ZSQR) ("Z Squared" or the "Company"), a vertically integrated computing infrastructure company, today announced the completion of its business combination with Coeptis Therapeutics Holdings, Inc. ("Coeptis"). In connection with the business combination, the combined company has been renamed "Z Squared Inc." and its public shares are expected to commence trading on the Nasdaq Global Market under the ticker symbol "ZSQR" on Monday, April 27, 2026 (CUSIP: 98878K108). The closing follows the satisfaction of all con

    4/24/26 4:43:00 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing Application

    ~ Approval Marks Satisfaction of Key Closing Condition in Pending Merger ~ WEXFORD, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, today announced that Nasdaq has approved, subject to customary conditions and the closing of the proposed merger, the listing of the post-merger Company's common stock on the Nasdaq Global Market under the ticker symbol "ZSQR". The new listing is expected to become effective upon the closing of the proposed merger between the Company and Z Squared, Inc., pursuant to which Z Squared will become a wholly owned subsidiary of Coeptis and th

    4/7/26 12:05:56 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Receives Shareholder Approval Towards Z Squared Merger

    WEXFORD, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, today announced that its shareholders have voted to approve the previously announced merger with Z Squared Inc. The transaction was approved on January 30, 2026, by Coeptis' shareholders. In connection with the consummation of the business combination, Z Squared will become a wholly owned subsidiary of Coeptis. The transaction remains subject to satisfaction of the remaining conditions to closing. Additional details regarding the shareholder vote and the proposed merger are included in the Company's Form 8-K f

    2/5/26 4:00:00 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COEP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Harris Jeffery Keeslar

    3 - Z Squared Inc. (0001759186) (Issuer)

    7/7/26 9:16:58 AM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Marketing Officer Schadel Christopher Ryan

    4 - Z Squared Inc. (0001759186) (Issuer)

    6/8/26 4:01:32 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Bsg Series Cm, Llc disposed of 41,521,276 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Z Squared Inc. (0001759186) (Issuer)

    5/15/26 9:11:17 AM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COEP
    Leadership Updates

    Live Leadership Updates

    View All

    Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

    Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa., Aug. 30, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed Chief Scientific and Medical Officer of Coeptis following the completion of an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs.

    8/30/23 1:00:00 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

    15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities WEXFORD, Pa., May 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today the appointment of Brian Cogley, MBA, to the position of Chief Financial Officer (CFO) effective immediately. Mr. Cogley brings 15 years of accounting and finance experience to Coeptis, having previously held positions of increasing authority at two "Big 4" accounting firms and served on the management teams of multiple companies in diverse in

    5/17/23 8:30:00 AM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COEP
    Financials

    Live finance-specific insights

    View All

    Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

    Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors WEXFORD, Pa., Aug. 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. ("Deverra") related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generat

    8/17/23 7:30:00 AM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $COEP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Coeptis Therapeutics Holdings Inc.

    SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

    11/14/24 3:59:49 PM ET
    $COEP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care